Treatment of Helicobacter pylori infection in 2018

• Published in: Helicobacter (Cambridge, Mass.) Vol. 23; no. S1; pp. e12519 - n/a
• Main Authors: O'Morain, Neil R., Dore, Maria P., O'Connor, Anthony J. P., Gisbert, Javier P., O'Morain, Colm A.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01-09-2018
• Subjects: Anti-Bacterial Agents - therapeutic use; Antibiotics; Bismuth; Bismuth‐based quadruple therapy; Clarithromycin; Eradication; eradication therapy; Guidelines; Helicobacter Infections - drug therapy; Helicobacter pylori; Helicobacter pylori - pathogenicity; Humans; Levofloxacin; Proton Pump Inhibitors - therapeutic use; resistance; Side effects; standard triple therapy; tailored therapy; Therapy; tailored therapy; clarithromycin; eradication therapy; Bismuth-based quadruple therapy; resistance; standard triple therapy
• ISSN: 1083-4389; 1523-5378
• DOI: 10.1111/hel.12519

Treatment options for the eradication of Helicobacter pylori continue to evolve. There have been many guidelines for H. pylori treatment published, which may lead to some confusion. However, most are in agreement with the most recent iteration of the Maastricht treatment guidelines. Triple therapy is still the most frequently used treatment, especially in areas of low clarithromycin resistance. Its best results are achieved when taken for a minimum of 10 days and with high‐dose acid suppression. Quadruple therapy is gaining in popularity particularly in areas with increasing resistance to standard triple therapy. Whether three antibiotics, or bismuth and two antibiotics are used, excellent eradication rates are achieved, albeit with increased side effects. Levofloxacin second‐line therapy is widely used; however bismuth, when available, is an increasingly successful option. Sequential therapy is challenging in terms of compliance and is no longer recommended. This past year witnessed a notable increase in the number of studies based on antimicrobial susceptibility testing and tailored eradication therapy, reflecting the role of culture‐guided treatment, which may well represent the future of H. pylori treatment and prevent the inappropriate use of antibiotics.